Robert Finke's questions to Sarepta Therapeutics Inc (SRPT) leadership • Q2 2024
Question
Robert Finke asked if manufacturing capacity is anticipated to be a gating factor at any point between now and reaching peak sales for ELEVIDYS.
Answer
CEO Douglas Ingram stated definitively that the company does not envision manufacturing being a bottleneck for the next few years. He added that by the time it could become a rate-limiter, the company hopes to be using its suspension-based manufacturing process, which should not have limitations. He concluded they are in a very good position from a supply perspective.